Glenmark's Game-Changing Move: Epinephrine Injection Launch Injects New Life into US Portfolio

Glenmark Pharmaceuticals Inc., USA has unveiled its latest pharmaceutical breakthrough: Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial. This strategic launch, announced on February 27, 2025, not only expands Glenmark's critical care offerings but also secures a 180-day competitive generic therapy (CGT) exclusivity. The product, bioequivalent to BPI Labs' reference drug, targets a market that saw annual sales of $42.7 million in 2024. This move underscores Glenmark's commitment to providing affordable, high-quality alternatives in the US healthcare landscape, potentially boosting its market position and investor appeal.

 

Source: Glenmark Pharmaceuticals Ltd. regulatory filing to NSE and BSE